文献速递乳腺癌

HER2突变转移性乳腺癌中HER激酶抑制的疗效与应答决定因素

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
PubMed 文献 · Cancer Discov · 2019-12-05

该研究在81例HER2突变转移性乳腺癌患者中探索不可逆泛HER激酶抑制剂来那替尼单用或联合氟维司群的疗效。总体缓解率在有无雌激素受体阻断时相似,但ER+患者接受联合治疗的无进展生存期和缓解持续时间似更长。基线共存HER2或HER3激活改变与不良治疗结局相关,疾病进展时观察到多种HER2激活事件及守门员改变。

要点

  • HER2突变是乳腺癌可靶向治疗亚型,来那替尼单用或联合氟维司群均显示活性。
  • ER+患者接受来那替尼联合氟维司群的无进展生存期和缓解持续时间似更长。
  • 基线共存HER2或HER3激活改变及获得性耐药改变可导致来那替尼原发或继发耐药。

核心结论

  • HER2突变是乳腺癌的治疗靶点,但通路中共存激活基因组事件可能改变对不可逆HER激酶抑制的敏感性。
  • 共存的额外HER信号改变可能促进对来那替尼的原发性和获得性耐药。

研究设计与样本

  • 研究纳入81例HER2突变转移性乳腺癌患者,探索来那替尼单用或联合氟维司群的疗效。

主要发现

  • 总体缓解率在有无雌激素受体阻断时相似。
  • ER+患者接受联合治疗的无进展生存期和缓解持续时间似更长,但研究未设计直接比较。
  • 基线共存激活HER2或HER3改变与不良治疗结局相关。
  • 疾病进展时,在较高比例从来那替尼获得临床获益的患者中观察到多种HER2激活事件及守门员改变。

临床怎么用

  • HER2突变转移性乳腺癌可考虑不可逆泛HER激酶抑制策略。
  • 治疗决策需关注基线共存的HER2或HER3激活改变,其可能提示原发耐药。

局限性

  • 研究未设计直接比较,ER+患者联合治疗的无进展生存期和缓解持续时间优势需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data define HER2 mutations as a therapeutic target in breast cancer and suggest that coexistence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib. SIGNIFICANCE: HER2 mutations define a targetable breast cancer subset, although sensitivity to irreversible HER kinase inhibition appears to be modified by the presence of concurrent activating genomic events in the pathway. These findings have implications for potential future combinatorial approaches and broader therapeutic development for this genomically defined subset of breast cancer.This article is highlighted in the In This Issue feature, p. 161.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Smyth LM, Piha-Paul SA, Won HH, et al. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discov. 2019. PMID: 31806627. doi:10.1158/2159-8290.CD-19-0966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。